Recent Acquisition Pulmodyne was acquired by Intersurgical in 2022, expanding its global footprint and product distribution channels. This strategic move presents opportunities to leverage Intersurgical's international network for new sales and partnership development in respiratory and emergency care markets.

Partnership Growth The company's recent partnership with fluidIQ for respiratory technology development indicates active collaboration in innovative respiratory solutions. This opens avenues for engaging with Pulmodyne's R&D efforts and offering complementary products or services that enhance their technological capabilities.

Diverse Market Focus Pulmodyne serves acute care, emergency, prehospital, and homecare segments, providing multiple touchpoints for sales engagement. Tailoring solutions across these areas can meet diverse customer needs and expand market penetration within each sector.

Product Development & Innovation With a focus on proprietary respiratory and airway products, Pulmodyne shows continued innovation and product launches, such as the O2-MAX™ with nebulizer. Opportunities exist to introduce new respiratory devices or enhancements aligned with their development roadmap.

Strategic Leadership Under the leadership of president Andrew Shurig and a committed development team, Pulmodyne is positioned for growth and expansion. Building relationships with key decision-makers could facilitate entry into their expanding product lines and foster long-term collaborations.